Multisystem Processes & Disorders

Malaria: diagnosis, treatment, and prophylaxis

Clinical Overview and When to Suspect Malaria

— P. falciparum — most lethal, sub-Saharan Africa, causes severe/cerebral malaria

— P. vivax — Asia, Latin America, Horn of Africa; relapses from hypnozoites

— P. ovale — West Africa; also relapses

— P. malariae — chronic low-grade parasitemia, nephrotic syndrome

— P. knowlesi — Southeast Asia (Borneo, Malaysia); zoonotic from macaques, can be severe

— Fever within 1 year of travel to an endemic area (Africa, South/Southeast Asia, Oceania, parts of Latin America)

— Returning Peace Corps, military, missionaries, visiting friends/relatives (VFR travelers are the highest-risk US group because they often skip prophylaxis)

— Unexplained hemolytic anemia, thrombocytopenia, or jaundice post-travel

— Recipients of blood transfusion or organ transplant from endemic donor; rarely congenital or airport/needlestick malaria

Malaria = febrile illness in a returned traveler or migrant from an endemic region until proven otherwise. The five human species:

Incubation: typically 7–30 days; P. falciparum usually <4 weeks, P. vivax/ovale may relapse months–years later after primary infection

Suspect malaria in any patient with:

Classic periodicity (tertian every 48 h for vivax/ovale, quartan every 72 h for malariae) is rarely seen at initial presentation—do not require it to test

Step 3 management: A fever in a returned traveler from sub-Saharan Africa is a medical emergency. Order thick and thin blood smears immediately; do not wait for outpatient workup or empiric antibiotics for "presumed viral illness." Delayed diagnosis of falciparum is the leading malpractice scenario.

Board pearl: US-acquired malaria is exceedingly rare but possible (2023 Florida/Texas autochthonous P. vivax cases)—ask about mosquito exposure even without travel if the smear is positive.

Notify the state health department on confirmation; malaria is a nationally notifiable disease.

Presentation Patterns and Key History

— Headache, myalgias, fatigue, malaise

— Nausea, vomiting, abdominal pain, diarrhea (especially in children)

— Cough, mild dyspnea

— Jaundice from hemolysis

— Impaired consciousness, seizures, coma (cerebral malaria)

— Respiratory distress (ARDS, acidosis)

— Hypoglycemia, especially with quinine therapy or in pregnancy

— Oliguria, dark urine ("blackwater fever" = massive hemolysis with hemoglobinuria)

— Spontaneous bleeding, DIC

— Hyperparasitemia (>5% in non-immune, >10% in semi-immune)

— Specific countries/regions visited, rural vs urban, duration, dates of arrival and departure

— Chemoprophylaxis: drug, adherence, completion after return (atovaquone-proguanil stops 7 d post, mefloquine/doxycycline continue 4 weeks)

— Bed net use, repellent, evening outdoor exposure

— Prior malaria episodes (semi-immunity wanes within ~1–2 years after leaving endemic area)

— G6PD status (relevant for primaquine/tafenoquine)

— Pregnancy status

— Transfusions, IV drug use, shared needles

Cardinal symptom: fever, often with rigors, drenching sweats, and defervescence ("cold–hot–wet" paroxysm). Periodicity may be absent in the first week.

Associated symptoms (nonspecific, mimics flu/sepsis/gastroenteritis):

Red-flag features suggesting severe falciparum malaria:

Essential history elements:

Key distinction: A traveler who took prophylaxis can still get malaria—prophylaxis reduces but does not eliminate risk, and adherence is often imperfect. Never use "took Malarone" to rule it out.

Board pearl: P. vivax/ovale relapse can occur months to years after exposure because hypnozoites lie dormant in the liver. Always ask about remote travel in patients presenting with otherwise unexplained recurrent fevers.

VFR travelers (visiting friends and relatives) carry the highest US morbidity—counsel pre-travel even for "going home" trips.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Tachycardia proportional to fever

— Hypotension suggests severe disease, sepsis-like "algid malaria," or concurrent gram-negative bacteremia

— Tachypnea + Kussmaul breathing → metabolic (lactic) acidosis, a severity criterion

— Hypoxia → pulmonary edema/ARDS (worsens after starting treatment due to capillary leak)

— Splenomegaly — classic, develops over days to weeks; tender splenomegaly raises concern for splenic rupture, particularly with P. vivax

— Hepatomegaly with tenderness

— Right upper quadrant pain may mimic cholangitis

— Altered mental status, GCS drop

— Generalized seizures

— Decerebrate/decorticate posturing

— Retinal hemorrhages and "malarial retinopathy" (whitening, vessel changes) on funduscopy—highly specific in endemic pediatrics

General: ill-appearing, febrile (often >39 °C), diaphoretic during paroxysm; may be afebrile between paroxysms

Vitals & hemodynamics:

HEENT: scleral icterus from hemolysis; pallor of conjunctivae

Cardiopulmonary: usually clear lungs early; crackles or rales = ARDS/pulmonary edema (especially in pregnancy after fluid resuscitation)

Abdomen:

Neurologic (cerebral malaria, almost always P. falciparum):

Skin: jaundice; petechiae uncommon (think dengue if prominent)

Notably absent: lymphadenopathy and rash—if present, consider alternative diagnoses (typhoid, rickettsiosis, dengue, viral hemorrhagic fever)

Step 3 management: Use WHO severe malaria criteria at bedside: impaired consciousness, prostration, multiple convulsions, acidosis, hypoglycemia (<40 mg/dL), severe anemia (Hb <7 adults/<5 kids), AKI, jaundice with parasitemia, pulmonary edema, shock, abnormal bleeding, hyperparasitemia, hyperlactatemia (>5). Any one criterion → IV artesunate + ICU.

Board pearl: Lack of splenomegaly does not rule out malaria, especially in the first paroxysms or in semi-immune adults.

Diagnostic Workup — Initial Labs / Imaging / Biomarkers

— Thick smear = sensitive screen, detects parasites at low density

— Thin smear = species identification and parasitemia quantification (% infected RBCs)

— Send STAT; if initial smear negative but suspicion remains, repeat every 12–24 hours for 3 sets (72 h) before excluding malaria

— Notify the lab—techs must look specifically for parasites

— BinaxNOW Malaria detects HRP-2 (falciparum) and aldolase (pan-malarial)

— Useful when expert microscopy unavailable; confirm with smear for species and quantification

— Falciparum strains with pfhrp2 deletions can give false negatives

— CBC: thrombocytopenia is the most consistent finding; normocytic anemia from hemolysis; leukocytes usually normal/low

— Reticulocytes elevated; LDH high, haptoglobin low, indirect bilirubin high (hemolysis)

— BMP: AKI, hyponatremia, hyperkalemia from hemolysis, acidosis with elevated lactate

— LFTs: mild transaminitis, elevated indirect and direct bilirubin

— Glucose: hypoglycemia, particularly in pregnancy/children/quinine therapy—check q4h in severe cases

— Coags: DIC in severe disease

— Blood cultures: rule out concurrent bacteremia (algid malaria, nontyphoidal Salmonella)

— UA: hemoglobinuria in blackwater fever

— Pregnancy test in all women of reproductive age

— G6PD level before primaquine/tafenoquine

Gold standard: Giemsa-stained thick and thin peripheral blood smears

Rapid diagnostic tests (RDTs):

PCR: highest sensitivity/specificity, species-specific, mixed infections, low parasitemia—use for confirmation or when smear/RDT discordant; turnaround limits acute utility

Supportive labs:

CCS pearl: Order "malaria smears, thick and thin, STAT, repeat q12–24h ×3 if negative" plus CBC, CMP, LDH, haptoglobin, coags, lactate, blood cultures, glucose, UA, and pregnancy test on the initial CCS clock minute.

Board pearl: Isolated thrombocytopenia in a febrile traveler is malaria until proven otherwise.

Diagnostic Workup — Advanced or Confirmatory Studies

— P. falciparum: small ring forms, multiple rings per RBC, banana-shaped gametocytes, no schizonts in peripheral blood, normal-sized RBCs, high parasitemia possible

— P. vivax: enlarged RBCs with Schüffner dots, ameboid trophozoites, all stages visible

— P. ovale: oval RBCs with fimbriated edges, Schüffner dots

— P. malariae: band-form trophozoites, "rosette" schizonts, normal RBC size, low parasitemia

— P. knowlesi: morphologically resembles P. malariae but can have falciparum-like severity; confirm by PCR

— Mixed infections suspected

— P. knowlesi possible (Southeast Asia)

— Smear morphology ambiguous

— Drug resistance surveillance (CDC reference lab)

— CXR if hypoxia, dyspnea, or before fluid resuscitation in severe cases (ARDS risk)

— Head CT if focal deficits or before LP in altered patients with suspected cerebral malaria

— Abdominal US if splenic rupture suspected (sudden LUQ pain, hypotension, falling Hb)

Species identification on thin smear morphology (high-yield):

Quantify parasitemia at diagnosis and serially (q12–24 h once treated) until <1% and clinically improving—critical for severity grading and response monitoring

PCR / molecular speciation: indicated when:

G6PD activity (quantitative): mandatory before primaquine (vivax/ovale radical cure) and tafenoquine; qualitative tests acceptable for primaquine but tafenoquine requires quantitative ≥70% normal activity

CYP2D6 genotyping: poor metabolizers may have primaquine failure (not routinely required but explains relapse)

Imaging:

Lumbar puncture: consider in altered patients to exclude bacterial meningitis; in cerebral malaria CSF is typically normal or mildly elevated protein

Step 3 management: Once species and parasitemia known, decide severe vs uncomplicated and chloroquine-sensitive vs resistant region—these two axes drive every therapeutic choice.

Board pearl: Banana-shaped gametocytes = P. falciparum is the most testable smear finding.

Risk Stratification and First-Line Management Logic

— P. falciparum / P. knowlesi → assume drug resistance, treat as resistant

— P. vivax / P. ovale → must add radical cure for hypnozoites (primaquine or tafenoquine) after G6PD testing

— P. malariae → chloroquine sensitive everywhere

— Chloroquine-resistant P. falciparum = essentially everywhere it occurs (sub-Saharan Africa, Asia, South America, Oceania)

— Chloroquine-sensitive P. falciparum survives only in parts of Central America west of Panama Canal, Haiti, and Dominican Republic

— Chloroquine-resistant P. vivax = Papua New Guinea, Indonesia (Oceania)

— All confirmed P. falciparum infections in non-immune patients warrant inpatient admission for at least 24 h to monitor parasitemia and clinical course, even if uncomplicated

— Non-falciparum infections in stable patients can occasionally be treated outpatient with close follow-up

Step 1 — Severe vs uncomplicated: Apply WHO severe malaria criteria. Any single criterion mandates IV artesunate + ICU admission, regardless of species or parasitemia.

Step 2 — Identify species:

Step 3 — Region of acquisition determines chloroquine sensitivity:

Step 4 — Disposition:

Step 5 — Pregnancy: alters every choice (see chunk 10)

Step 6 — Contact CDC Malaria Hotline (770-488-7788 weekdays; 770-488-7100 after hours) for any severe case, P. knowlesi, treatment failure, or to obtain IV artesunate (commercially available in US since 2020; replaces former CDC IND quinidine pathway)

CCS pearl: First three orders for any suspected severe malaria: (1) IV access × 2 + ICU admission, (2) IV artesunate 2.4 mg/kg STAT, (3) fingerstick glucose q4h with D10 infusion as needed.

Board pearl: Quinidine gluconate IV is no longer first-line in the US—IV artesunate has replaced it because of superior mortality benefit (SEAQUAMAT, AQUAMAT trials).

Pharmacotherapy — First-Line Drug Regimens

— IV artesunate 2.4 mg/kg at 0, 12, 24 h, then daily; minimum 3 doses (≥24 h)

— Transition to full oral course once parasitemia <1% and tolerating PO: artemether-lumefantrine, atovaquone-proguanil, or quinine + doxycycline

— Monitor for post-artesunate delayed hemolysis (PADH): weekly CBC + LDH/haptoglobin × 4 weeks

— Artemether-lumefantrine (Coartem) — 6-dose regimen over 3 days, take with fatty food

— Alternative: atovaquone-proguanil (Malarone) — 4 tabs daily × 3 days, with food

— Alternative: quinine sulfate + doxycycline (or tetracycline/clindamycin) × 7 days

— Alternative: mefloquine (avoid: neuropsychiatric effects, resistance in SE Asia)

— Chloroquine phosphate 1 g, then 500 mg at 6, 24, 48 h (or hydroxychloroquine)

— Primaquine 30 mg base daily × 14 days — requires documented G6PD normal

— Tafenoquine 300 mg × 1 dose — single-dose alternative, requires quantitative G6PD ≥70%

— In G6PD deficiency: weekly primaquine 45 mg × 8 weeks under hematology guidance, or omit and counsel on relapse risk

— Artesunate: PADH, reticulocytopenia, transaminitis

— Quinine/quinidine: cinchonism (tinnitus, headache), hypoglycemia, QT prolongation, hypotension

— Mefloquine: vivid dreams, anxiety, psychosis, seizures—avoid in psychiatric/seizure history

— Atovaquone-proguanil: well tolerated, GI upset

— Primaquine/tafenoquine: hemolysis in G6PD deficiency, methemoglobinemia

Severe malaria (any species, any region):

Uncomplicated chloroquine-resistant P. falciparum (most regions):

Uncomplicated chloroquine-sensitive infection (P. malariae, P. ovale, sensitive-region P. vivax/falciparum):

Radical cure for P. vivax/P. ovale (eliminates hepatic hypnozoites, prevents relapse):

Key drug toxicities:

Board pearl: Never give primaquine without checking G6PD first—classic test question.

Step 3 management: Always pair vivax/ovale blood-stage treatment with hypnozoite eradication; otherwise relapse is the rule.

Expanded Pharmacology — Drug Choice by Scenario and Resistance

— Now commercially available in US (Artesunate for Injection)—pharmacy can stock; CDC no longer required to ship

— Reconstitute and infuse over 1–2 min; no loading dose adjustment for renal/hepatic disease

— If unavailable, give IV quinidine gluconate (continuous telemetry, QTc monitoring) as bridge while sourcing artesunate

— Begin oral therapy when patient tolerates PO, parasitemia clearly falling, and clinically improving

— Do not use mefloquine as follow-on after artesunate in patients with cerebral malaria (additive neurotoxicity)

— Artemether-lumefantrine: avoid with CYP3A4 inhibitors and QT-prolonging drugs; contraindicated in 1st trimester (except severe malaria when benefits outweigh)

— Atovaquone-proguanil: reduce dose with renal failure (avoid if CrCl <30); avoid in pregnancy (data limited) and breastfeeding infants <5 kg

— Doxycycline: avoid pregnancy and children <8 y

— Mefloquine: contraindicated in psychiatric history, seizure disorder, cardiac conduction abnormalities

— Chloroquine: caution in psoriasis, porphyria, epilepsy

— Greater Mekong subregion (Cambodia, Thailand, Myanmar, Laos, Vietnam): artemisinin partial resistance + mefloquine resistance → use atovaquone-proguanil or artemether-lumefantrine with extended monitoring

— Papua New Guinea/Indonesia: chloroquine-resistant P. vivax → treat as resistant

— Exchange transfusion no longer routinely recommended even at high parasitemia—not shown to improve mortality beyond IV artesunate

— Avoid corticosteroids in cerebral malaria—increased coma duration and complications

— Cautious fluid resuscitation; FEAST trial showed bolus fluids worsen outcomes in pediatric severe febrile illness

IV artesunate logistics:

Pre-referral artesunate suppositories: rural/resource-limited settings—gives a head start before transfer

Switching IV → PO:

Drug interactions / contraindications:

Drug-resistance hotspots to recognize:

Adjunctive measures:

CCS pearl: Order continuous telemetry + q4h glucose checks for any patient on quinine/quinidine; hypoglycemia and torsades are predictable.

Board pearl: Artemisinin monotherapy is never used—always combine to prevent resistance (artemisinin-based combination therapy = ACT).

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher mortality from severe falciparum—physiologic reserve limits compensation for hemolysis, acidosis, AKI

— Lower threshold for ICU admission and IV artesunate

— Polypharmacy → review for QT-prolonging agents before mefloquine, quinine, chloroquine, artemether-lumefantrine; obtain baseline ECG

— Atovaquone-proguanil generally best tolerated for uncomplicated disease and prophylaxis

— Malaria itself causes AKI (acute tubular necrosis from hemoglobinuria, ischemia, sepsis)—monitor I/Os, daily creatinine

— Hemodialysis often required in severe disease; does not significantly remove artesunate (no dose adjustment)

— Atovaquone-proguanil: avoid prophylactic use if CrCl <30 mL/min; treatment can be given with caution

— Quinine: reduce dose by one-third if CrCl <10 or in dialysis; risk of accumulation and toxicity

— Chloroquine: dose-adjust in severe CKD

— Doxycycline: safe in renal failure

— Avoid nephrotoxins (NSAIDs, contrast) during acute phase

— Malaria causes hepatic dysfunction (zone 3 necrosis, cholestasis)—mild transaminitis expected; severe hepatic failure rare

— Artesunate: no dose adjustment but monitor LFTs

— Atovaquone-proguanil, quinine, mefloquine: caution in severe hepatic impairment

— Primaquine: generally safe but monitor; hypnozoite cure can be deferred if liver failure

— Nontyphoidal Salmonella bacteremia (especially with severe malaria in children/HIV)

— HIV co-infection worsens course; check HIV status

— Hepatitis A/E in returned travelers with jaundice and transaminitis

Elderly:

Renal impairment:

Hepatic impairment:

Concurrent infections to consider:

Step 3 management: Any elderly returned traveler with fever + thrombocytopenia + AKI = obtain malaria smears and blood cultures simultaneously; treat both empirically until results.

Board pearl: Post-artesunate delayed hemolysis affects up to 25%—weekly CBC × 4 weeks is standard post-discharge in all patients but especially the elderly with marginal reserve.

Special Populations — Pregnancy and Pediatrics

— Increased severity, hypoglycemia, pulmonary edema, anemia

— Placental sequestration of P. falciparum causes IUGR, prematurity, stillbirth, low birth weight, congenital malaria

— Fever itself raises risk of preterm labor

— Severe malaria, any trimester: IV artesunate — life-saving, benefits outweigh theoretical fetal risks

— Uncomplicated, 1st trimester: quinine + clindamycin × 7 days (historically preferred); artemether-lumefantrine now acceptable per WHO when alternatives unsuitable

— Uncomplicated, 2nd/3rd trimester: artemether-lumefantrine first-line

— Avoid: doxycycline, tetracycline, primaquine, tafenoquine, atovaquone-proguanil (limited data)

— Vivax/ovale relapse prevention: weekly chloroquine prophylaxis until delivery and breastfeeding completed, then G6PD test → primaquine

— Mefloquine or chloroquine (region-dependent)—both pregnancy-acceptable

— Ideally defer non-essential travel to endemic areas during pregnancy

— Children present with vomiting, diarrhea, irritability, seizures—malaria mimics gastroenteritis and meningitis

— Severe anemia, hypoglycemia, and cerebral malaria are leading killers

— IV artesunate is first-line; pediatric dosing 2.4 mg/kg (≥20 kg) or 3.0 mg/kg (<20 kg)

— Artemether-lumefantrine approved for children ≥5 kg

— Avoid doxycycline <8 y, primaquine in infants <6 mo, atovaquone-proguanil <5 kg

Pregnancy is high-risk:

Treatment in pregnancy:

Chemoprophylaxis in pregnant travelers:

Pediatrics:

Breastfeeding: small amounts excreted; most antimalarials compatible except tafenoquine and primaquine (until infant G6PD status known)

Congenital malaria: test infant smears if mother infected peripartum; transplacental transmission possible

Board pearl: Pregnancy + sub-Saharan travel + fever + hypoglycemia = severe P. falciparum until disproven; admit and give IV artesunate empirically while awaiting smears.

Step 3 management: Co-manage with OB and ID; intermittent preventive treatment in pregnancy (IPTp with sulfadoxine-pyrimethamine) applies to endemic residents, not US travelers.

Complications and Adverse Outcomes

— Diffuse encephalopathy, seizures, coma; mortality 15–20% even with treatment

— Sequelae: cognitive deficits, epilepsy, ataxia, especially in pediatric survivors

— ATN from hemoglobinuria ("blackwater fever") and ischemia

— May require RRT; usually reversible

— Often develops 1–4 days after starting treatment due to capillary leak

— Pregnancy is highest risk; restrict fluids

— Multifactorial: hepatic glucose impairment, quinine-induced insulin release, fasting

— Recurrent—dextrose infusion + q1–4h glucose monitoring

— Drop in Hb 7–21 days after IV artesunate; immune-mediated destruction of "pitted" RBCs

— Mandatory weekly CBC, reticulocyte, LDH, haptoglobin × 4 weeks post-treatment

— Transfuse if symptomatic

Cerebral malaria (P. falciparum):

Severe anemia: from hemolysis, suppressed erythropoiesis, splenic sequestration—may need transfusion

Acute kidney injury:

Pulmonary edema / ARDS:

Hypoglycemia:

Metabolic (lactic) acidosis: sequestered parasites cause microvascular obstruction; poor prognostic marker

DIC and bleeding: thrombocytopenia, coagulopathy

Splenic rupture: classically P. vivax; sudden LUQ pain → CT, surgical consult; vaccinate post-splenectomy

Algid malaria: gram-negative bacteremia (especially nontyphoidal Salmonella) co-infection—blood cultures and broad-spectrum antibiotics in any septic-appearing patient

Post-artesunate delayed hemolysis (PADH):

Tropical splenomegaly / hyperreactive malarial splenomegaly: chronic immune response, massive spleen, anemia—responds to long-term antimalarials

Nephrotic syndrome: classic association with chronic P. malariae—immune-complex glomerulopathy, poor response to steroids

Blackwater fever: massive intravascular hemolysis, dark urine, AKI; associated with quinine, G6PD deficiency, repeated infections

Board pearl: PADH is the most commonly missed post-discharge complication—must be communicated explicitly to PCP and patient at transition of care.

CCS pearl: Trend Hb, retics, LDH, haptoglobin, Cr, glucose, parasitemia daily inpatient; weekly Hb × 4 weeks outpatient.

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Any confirmed P. falciparum or P. knowlesi (non-immune patient)

— Any parasitemia >2%

— Inability to tolerate PO

— Pregnancy

— Significant comorbidity (CKD, CHF, immunocompromise, asplenia, age >65)

— Unreliable follow-up or social barriers

— GCS drop, seizures, prostration

— Parasitemia >5% (non-immune) or >10% (semi-immune)

— Hb <7 g/dL (adults) or <5 (children)

— Bilirubin >3 with parasitemia >100,000/μL

— Cr >3 or urine output <0.5 mL/kg/h

— Lactate >5, pH <7.25, bicarb <15

— Glucose <40 mg/dL

— Pulmonary edema/ARDS, SpO₂ <92% on RA

— Shock (SBP <80, lactate, cool extremities)

— Spontaneous bleeding/DIC

— Hemoglobinuria

— Infectious Diseases: all confirmed cases

— CDC Malaria Hotline (770-488-7788): severe disease, treatment failure, drug sourcing, knowlesi

— OB: any pregnant patient

— Hematology: PADH, G6PD-deficient patient needing radical cure

— Nephrology: AKI requiring RRT

— Critical Care/Pulmonology: ARDS

— Local hospital lacks IV artesunate, ICU, or dialysis

— Pediatric severe malaria → tertiary pediatric center

Admit ALL of the following to inpatient:

ICU criteria — any one WHO severe malaria feature:

Consultations:

Transfer indications:

CCS pearl: On the CCS clock—admit to ICU, IV artesunate, ID consult, OB consult (if pregnant), report to public health, place on respiratory/standard precautions, q1h vitals, q4h glucose, q12h parasitemia, daily CBC/CMP/lactate—then advance the clock.

Step 3 management: Do not delay first artesunate dose for transfer—give it before the ambulance leaves if available.

Board pearl: A patient with "uncomplicated" malaria who develops new tachypnea or somnolence has progressed to severe disease until proven otherwise—escalate immediately.

Key Differentials — Same-Category (Tropical/Travel) Infections

— Aedes mosquito; abrupt high fever, severe retro-orbital headache, myalgia ("breakbone"), rash, leukopenia, thrombocytopenia

— Hemorrhagic features (petechiae, positive tourniquet test) more prominent than malaria

— Diagnosis: NS1 antigen (first week), IgM/IgG, PCR

— No specific therapy; supportive care, avoid NSAIDs/aspirin

— Salmonella Typhi/Paratyphi; stepwise fever, relative bradycardia (Faget sign), rose spots, hepatosplenomegaly, abdominal pain

— Leukopenia, mild transaminitis

— Blood culture × 3 most sensitive in week 1; treat with ceftriaxone or azithromycin (resistance to fluoroquinolones common in South Asia)

Dengue:

Typhoid (enteric) fever:

Chikungunya: abrupt fever + severe polyarthralgia lasting weeks; same Aedes vector as dengue

Zika: fever, rash, conjunctivitis, arthralgia; teratogenic (microcephaly)—pregnancy implications

Leptospirosis: freshwater exposure, biphasic fever, conjunctival suffusion, jaundice + AKI (Weil disease), myalgias; treat doxycycline or ceftriaxone

Rickettsioses (African tick-bite fever, scrub typhus, Mediterranean spotted fever): eschar at bite site, rash, regional lymphadenopathy; doxycycline empiric

Viral hemorrhagic fevers (Ebola, Lassa, Marburg, CCHF): West/Central Africa, hemorrhage, contact precautions, public health emergency

Amebic liver abscess: E. histolytica, RUQ pain + fever + hepatomegaly, single right-lobe abscess on imaging; treat metronidazole + luminal agent (paromomycin)

Schistosomiasis (Katayama fever): freshwater exposure 4–8 weeks prior, eosinophilia, fever, urticaria

Acute HIV / acute hepatitis A/B/E: especially in travelers with high-risk exposures

Key distinction: Malaria typically has thrombocytopenia + hemolytic anemia without rash and without lymphadenopathy; dengue has rash + retro-orbital pain; typhoid has bradycardia + rose spots; rickettsiosis has eschar.

Board pearl: A returned traveler can have co-infection—always work up broadly with smears, blood cultures, dengue NS1, HIV, hepatitis panel, and CXR.

Key Differentials — Other-Category Causes of Fever in a Returned Traveler

Influenza/COVID/respiratory viruses: most common cause of fever in returned travelers worldwide; obtain respiratory panel

Community-acquired pneumonia: Strep pneumoniae, Legionella (especially with hotel/cruise exposure)

Urinary tract infection / pyelonephritis: especially in women post-travel

Acute bacterial gastroenteritis: Campylobacter, Shigella, ETEC—usually self-limited

Tuberculosis: subacute fever, night sweats, cough, weight loss; consider in travelers from high-prevalence regions and migrants

Endocarditis: especially in IV drug users or with prosthetic valves

Acute HIV seroconversion: mononucleosis-like illness 2–4 weeks after exposure; HIV RNA viral load is diagnostic

Hepatitis A/B/E: jaundice, transaminitis, fecal-oral or sexual exposure

Meningococcemia: Hajj pilgrims, sub-Saharan "meningitis belt"—fever, rash, hypotension; emergent ceftriaxone

Drug fever / serum sickness: new medications, including antimalarials themselves

Hematologic malignancy: lymphoma, leukemia presenting with B symptoms—consider in atypical presentations

Thrombotic microangiopathies (TTP/HUS): fever, thrombocytopenia, MAHA, AKI, neurologic changes—can mimic severe malaria; check ADAMTS13, schistocytes; plasma exchange if TTP

DRESS / hypersensitivity syndrome: travelers on new prophylaxis (sulfa, doxycycline)

Heat stroke / exertional rhabdomyolysis: in travelers to hot climates with exertion

Pulmonary embolism: long-haul flight risk—fever can be a presenting feature

Key distinction: Schistocytes + thrombocytopenia + AKI could be TTP, HUS, DIC, or severe malaria—a peripheral smear distinguishes (parasites in RBCs vs schistocytes alone).

Step 3 management: A "fever in returned traveler" workup is always: CBC with smear (malaria + schistocytes), CMP, LFTs, UA, blood cultures × 2, HIV, hepatitis panel, dengue NS1/IgM, CXR, respiratory viral panel, stool studies if diarrhea, pregnancy test. Tailor further by exposure history.

Board pearl: Eosinophilia + fever in a returned traveler is rarely malaria—think helminths (schistosomiasis, strongyloides, filaria, hookworm) or drug reaction.

Secondary Prevention / Discharge Plan and Chemoprophylaxis

— Afebrile and clinically improved

— Parasitemia <1% and falling

— Tolerating PO

— Completed minimum 24 h of artesunate (if severe)

— Full PO course prescribed

— Pregnancy/social supports addressed

— Completion of ACT (artemether-lumefantrine or atovaquone-proguanil)

— Primaquine 30 mg base × 14 days or tafenoquine 300 mg × 1 for vivax/ovale (G6PD confirmed)

— Iron/folate if anemic

— Antipyretics as needed

— Atovaquone-proguanil (Malarone): 1 tab daily; start 1–2 days before, continue 7 days after return; well tolerated; avoid CrCl <30 and pregnancy

— Doxycycline 100 mg daily: start 1–2 days before, continue 4 weeks after return; photosensitivity, esophagitis, avoid <8 y and pregnancy

— Mefloquine 250 mg weekly: start ≥2 weeks before, continue 4 weeks after; weekly dosing aids adherence; avoid psychiatric/seizure/cardiac conduction history

— Chloroquine (only chloroquine-sensitive regions): weekly; safe in pregnancy

— Tafenoquine (Arakoda) 200 mg daily × 3 loading, then weekly; requires G6PD ≥70%

— Primaquine 30 mg daily for primary and terminal prophylaxis in vivax-predominant areas (G6PD normal)

— DEET 20–30%, picaridin, or IR3535 repellents

— Permethrin-treated clothing and bed nets

— Long sleeves, screened/AC accommodations

— Avoid outdoor exposure dusk to dawn (Anopheles bites at night)

Discharge criteria after acute treatment:

Discharge medications:

Chemoprophylaxis for future travel — CDC region-specific recommendations:

Non-pharmacologic prevention (essential, often tested):

Vaccine: RTS,S and R21 malaria vaccines exist for pediatric endemic populations—not used for US travelers

Pre-travel counseling cadence: ideally 4–6 weeks before travel at a travel medicine clinic

Board pearl: VFR travelers underuse prophylaxis—proactively counsel them and prescribe, even for short trips "home."

Step 3 management: Prescribe prophylaxis with explicit start and stop dates; failure to continue 4 weeks after return is a leading cause of post-travel malaria with mefloquine/doxycycline.

Follow-Up, Monitoring, and Counseling

— Vitals q1h initially, then q4h

— Continuous telemetry if on quinine/quinidine

— Glucose q4h × 24 h, then q6h

— Parasitemia q12–24 h until <1%, then daily until negative ×2

— Daily CBC, CMP, LFTs, lactate, coags

— I/Os, daily weights

— Week 1, 2, 3, 4 visits or labs: CBC, reticulocyte, LDH, haptoglobin, BUN/Cr — screening for PADH and recovery of renal function

— Repeat smear at week 1 to confirm clearance if any concern

— Final ID follow-up at 4 weeks

— Counsel patient that fever within months to years should prompt re-evaluation

— Document G6PD status in chart for future episodes

— Explain hypnozoite biology and importance of completing 14-day primaquine course (adherence is poor)

— Photosensitivity with doxycycline; sun protection

— Avoid alcohol with metronidazole/tinidazole if used for co-infection

— Pregnancy planning—some antimalarials require washout before conception (tafenoquine: 3 months; mefloquine: 3 months)

— Future travel: pre-travel clinic referral, written prophylaxis plan

— Pre-travel counseling is a high-value, low-cost intervention reimbursed under preventive care

— Reduces ED visits and hospitalizations

Inpatient monitoring (severe malaria):

Post-discharge cadence:

Relapse surveillance (vivax/ovale):

Vaccinations and adjuncts after splenectomy (if splenic rupture occurred): pneumococcal, Hib, meningococcal, annual influenza; lifelong on-demand antibiotics

Counseling points:

Public health: Confirm case reported to state health department and CDC via ArboNET-equivalent malaria surveillance; provides genotyping for resistance and outbreak tracking

Quality and value:

CCS pearl: Schedule 1-week post-discharge clinic visit + weekly CBC × 4 weeks, and document G6PD status, parasitemia clearance, primaquine completion.

Board pearl: A returned traveler with anemia 2 weeks after artesunate completion is PADH, not relapse—check retics, LDH, haptoglobin; transfuse if symptomatic; do not reflexively re-treat for malaria.

Ethical, Legal, and Patient Safety Considerations

— Patients discharged on incomplete therapy (e.g., ED start of artemether-lumefantrine without follow-up) are at high risk of treatment failure—ensure full prescription in hand, confirmed pharmacy access, and a scheduled follow-up before discharge

— Communicate the PADH risk window explicitly to PCP and patient in writing

— Verify G6PD result before primaquine prescription is filled—pharmacy error here can cause life-threatening hemolysis

— IV artesunate is FDA-approved but still relatively new; counsel on PADH

— Off-label use in pregnancy (severe malaria) requires shared decision-making, but withholding artesunate from a pregnant patient with severe malaria is itself unsafe—document benefit-risk discussion

— Pediatric and pregnant patients: obtain guardian/spousal involvement per local norms but never delay treatment

— VFR travelers (often immigrant communities) have the highest malaria burden in the US; structural barriers (cost, insurance, language, time off) reduce pre-travel care—offer interpreter services, community health-worker referral, and address cost of prophylaxis

— Counterfeit antimalarials purchased abroad are a safety hazard—counsel patients to obtain medications from US pharmacies

— Failure to consider malaria in a febrile returned traveler is the leading malaria malpractice scenario

— Sundown handoff: if smear pending, explicit sign-out to overnight team with action plan

— Pre-travel counseling, prophylaxis prescribed, vaccinations given, and refusal documented

Mandatory reporting: Malaria is a nationally notifiable disease in the US. The clinician must report confirmed cases to the local/state health department, which forwards to CDC. Reporting is not optional and does not require patient consent—public health law preempts standard HIPAA restrictions for surveillance.

Transition-of-care safety:

Informed consent edge cases:

Health equity:

Diagnostic delays = liability:

Travel medicine documentation:

Step 3 management: Use a structured discharge checklist: medications dispensed, G6PD confirmed, PADH monitoring scheduled, public health reported, ID follow-up booked, pre-travel referral if applicable.

Board pearl: A pregnant patient refusing IV artesunate for fear of fetal harm—educate that untreated severe malaria is far more dangerous to mother and fetus than artesunate, document discussion, involve OB and ethics if persistent refusal.

High-Yield Associations and Rapid-Fire Clinical Facts

Banana-shaped (crescent) gametocytes → P. falciparum

Schüffner dots + enlarged RBCs → P. vivax (or ovale)

Band-form trophozoites + rosette schizonts → P. malariae

Resembles malariae but from Borneo/Malaysia and severe → P. knowlesi

Hypnozoites cause relapse → vivax and ovale only → primaquine or tafenoquine for radical cure

Duffy-negative blood group → resistant to P. vivax invasion (West African origin)

Sickle cell trait (HbAS) → protective against severe P. falciparum

HbC, thalassemia, G6PD deficiency → relative protection vs falciparum

Nephrotic syndrome (childhood, tropical) → think chronic P. malariae

Blackwater fever → massive intravascular hemolysis + hemoglobinuria + AKI; quinine, G6PD deficiency

Algid malaria → gram-negative bacteremia (often Salmonella) + severe falciparum

Splenic rupture → classically P. vivax

Cerebral malaria → P. falciparum only

Hypoglycemia → especially with quinine, pregnancy, children

Cinchonism → quinine/quinidine (tinnitus, headache, nausea, blurred vision)

Post-artesunate delayed hemolysis → weeks 1–4 after IV artesunate; weekly CBC

Mefloquine → neuropsychiatric side effects, contraindicated in psych/seizure history

Doxycycline → photosensitivity, esophagitis, avoid <8 y and pregnancy

Atovaquone-proguanil → daily, expensive, well-tolerated, avoid CrCl <30

First-line severe malaria worldwide → IV artesunate (SEAQUAMAT, AQUAMAT trials)

No role for steroids in cerebral malaria

No exchange transfusion recommended in current US guidelines

CDC Malaria Hotline: 770-488-7788 (business hours), 770-488-7100 (after hours)

Anopheles mosquito → night feeder; bed nets and DEET essential

Chloroquine-sensitive regions remaining: Central America west of Panama Canal, Hispaniola

Board pearl: "Fever + thrombocytopenia + returned traveler from sub-Saharan Africa + atypical lymphocytes absent" = malaria until disproven, not viral syndrome.

Board Question Stem Patterns

— Diagnosis: P. falciparum

— Next step: assess severity → if severe (any WHO criterion) IV artesunate + ICU; if uncomplicated artemether-lumefantrine + admit

— Diagnosis: P. vivax (relapse from hypnozoites)

— Treatment: chloroquine (if from sensitive region) + G6PD test → primaquine ×14 d or tafenoquine single dose

— Diagnosis: severe P. falciparum in pregnancy

— Treatment: IV artesunate immediately, ICU, OB consult, glucose monitoring, restrict fluids (ARDS risk)

— Diagnosis: post-artesunate delayed hemolysis (PADH)

— Action: supportive care, transfuse if symptomatic; do not re-treat empirically

— Best prophylaxis: atovaquone-proguanil (start 1–2 d before, continue 7 d after) or doxycycline or mefloquine; counsel DEET + bed nets

— Concept: artemisinin partial resistance in Greater Mekong—continue artesunate + add partner drug, consult CDC, use alternative ACT for follow-on

— Diagnosis: quartan malarial nephropathy (chronic P. malariae) → treat malaria; nephrotic syndrome responds poorly

— Diagnosis: dengue, not malaria—NS1 antigen, supportive care, avoid NSAIDs

Stem 1: "Returning Peace Corps volunteer from Nigeria with fever, headache, thrombocytopenia; smear shows ring forms and banana-shaped gametocytes."

Stem 2: "Patient returns from India 4 months ago, now with intermittent fevers q48h; smear shows enlarged RBCs with Schüffner dots."

Stem 3: "Pregnant traveler from Kenya, GCS 12, parasitemia 8%."

Stem 4: "Patient treated with IV artesunate 10 days ago for severe malaria, now Hb dropped from 11 to 7, elevated LDH, low haptoglobin."

Stem 5: "Healthy traveler planning safari in Tanzania, no medical history, no allergies."

Stem 6: "Pediatric patient from Cambodia with severe falciparum; treated with artemisinin, parasitemia not falling."

Stem 7: "Child with chronic edema, proteinuria, history of recurrent low-grade fevers from West Africa."

Stem 8: "Returned traveler with fever, rash, retro-orbital pain, low platelets, negative malaria smear ×3."

Board pearl: When the stem lists parasitemia >5%, lactate elevated, or any altered mental status, the answer is always IV artesunate, regardless of other options.

Step 3 management: Read the geography and trimester/age carefully—they change the answer choice more than the species does.

One-Line Recap

Malaria is a life-threatening parasitic infection that must be considered in every febrile returned traveler; diagnose with thick and thin Giemsa-stained smears (repeat ×3 over 72 h if negative), stratify by species and severity, treat severe disease with IV artesunate regardless of trimester or age, treat uncomplicated chloroquine-resistant falciparum with artemether-lumefantrine, eradicate vivax/ovale hypnozoites with G6PD-confirmed primaquine or tafenoquine, and prevent future cases with region-specific chemoprophylaxis plus DEET and bed nets.

Diagnosis: Thick smear screens, thin smear speciates and quantifies; repeat q12–24h ×3 before excluding. Look for banana-shaped gametocytes (falciparum), Schüffner dots (vivax/ovale), band forms (malariae).

Severity: WHO criteria—altered mental status, parasitemia >5%, acidosis, AKI, hypoglycemia, ARDS, severe anemia, jaundice with parasitemia, shock, DIC. Any one = ICU + IV artesunate 2.4 mg/kg at 0, 12, 24 h then daily.

Uncomplicated treatment: Artemether-lumefantrine or atovaquone-proguanil for resistant regions; chloroquine for sensitive regions or P. malariae. Always add primaquine or tafenoquine for vivax/ovale after G6PD testing.

Prevention: Pre-travel clinic 4–6 weeks before departure—atovaquone-proguanil, doxycycline, or mefloquine per CDC region map; DEET, permethrin clothing, bed nets, dusk-to-dawn avoidance; target VFR travelers and pregnant travelers specifically.

Watch for: Post-artesunate delayed hemolysis weeks 1–4 (weekly CBC), hypnozoite relapse months to years later, splenic rupture in vivax, nephrotic syndrome in chronic malariae, and co-infection with typhoid, dengue, or nontyphoidal Salmonella.

Board pearl: Fever + sub-Saharan Africa + thrombocytopenia = malaria emergency until proven otherwise—smear, admit, treat, report.